Mt. Whitney: Determinants of summit success and acute mountain sickness

Medicine and Science in Sports and Exercise

Volumn 40, Issue 10, 2008, Pages 1820-1827

  Wagner, Dale R ^a   D'Zatko, Kim ^a   Tatsugawa, Kevin ^b   Murray, Ken ^c   Parker, Daryl ^d   Streeper, Tim ^d   Willard, Kevin ^d  

^a UTAH STATE UNIVERSITY   (United States)

^b CALIFORNIA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

High altitude; Mountaineering; Risk factors; Susceptibility; Trekking

Indexed keywords

ANALGESIC AGENT; SELF ASSEMBLED MONOLAYER;

AGE; ALTITUDE ACCLIMATIZATION; ALTITUDE DISEASE; ARTICLE; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; SEX DIFFERENCE; TRAINING; UNITED STATES; ACUTE DISEASE; ADULT; MOUNTAINEERING; PATHOPHYSIOLOGY;

ACUTE DISEASE; ADULT; ALTITUDE SICKNESS; CALIFORNIA; FEMALE; HUMANS; MALE; MOUNTAINEERING; QUESTIONNAIRES;

EID: 58149314111     PISSN: 01959131     EISSN: 15300315     Source Type: Journal    
DOI: 10.1249/MSS.0b013e31817e91b8     Document Type: Article

References (29)

1. Baker-Salony S. How to Climb Mount Whitney in One Day. Wellington (NV): Dublin-Shore; 1997. p. 1-89.
2. Basnyat B, Lemaster J, Litch JA. Everest or bust: a cross sectional, epidemiological study of acute mountain sickness at 4243 meters in the Himalayas. Aviat Space Environ Med. 1999; 70:867-73.
3. Basnyat B, Subedi D, Sleggs J, et al. Disoriented and ataxic pilgrims: an epidemiological study of acute mountain sickness and high-altitude cerebral edema at a sacred lake at 4300 m in the Nepal Himalayas. Wilderness Environ Med. 2000;11:89-93.
4. Beidleman BA, Muza SR, Fulco CS, et al. Intermittent altitude exposures reduce acute mountain sickness at 4300 m. Clin Sci. 2004;106:321-8.
5. Brooks GA, Fahey TD, Baldwin KM. Exercise Physiology: Human Bioenergetics and Its Applications, 4th ed. New York: McGraw-Hill; 2005. p. 834-51.
6. Croft P, Benti W. Climbing Ml. Wliitney, 3rd ed. Bishop (CA): Spotted Dog Press; 2005. p. 1-132.
7. Fischer R, Vollmar C, Thiere M, et al. No evidence of cerebral edema in severe acute mountain sickness. Cephalalgia. 2004;24: 66-71.
8. Gaillard S, Dellasanta P, Loutan L, Kayser B. Awareness, prevalence, medication use, and risk factors of acute mountain sickness in tourists trekking around the Annapurnas in Nepal: a 12-year follow-up. High Alt Med Biol. 2004;5:410-9.
9. Hackett PH, Rennie D, Levine HD. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet. 1976;2: 1149-54.
10. Honigman B, Theis MK, Koziol-McLain J, et al. Acute mountain sickness in a general tourist population at moderate altitudes. Ann Intern Med. 1993;118:587-92.
11. Kallenberg K, Bailey DM, Christ S, et al. Magnetic resonance imaging evidence of cytotoxic cerebral edema in acute mountain sickness. J Cereb Blood Flow Metab. 2007;27:1064-71.
12. Levine BD, Zuckerman JH, deFilippi CR. Effect of high-altitude exposure in the elderly: the tenth mountain division study. Circulation. 1997;96:1224-32.
13. Maggiorini M, Buhler B, Walter M, Oelz O. Prevalence of acute mountain sickness in the Swiss Alps. Brit Med J. 1990;301: 853-5.
14. Morocz IA, Zientara GP, Gudbjartsson H, et al. Volumetric quantification of brain swelling after hypobaric hypoxia exposure. Exp Neurol. 2001;168:96-104.
15. Murdoch DR. Symptoms of infection and altitude illness among hikers in the Mount Everest region of Nepal. Aviat Space Environ Med. 1995;66:148-51.
16. Pesce C, Leal C, Pinto H, et al. Determinants of acute mountain sickness and success on Mount Aconcagua (6962 m). High Alt Med Biol. 2005;6:158-66.
17. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2006. ISBN 3-900051-07-0. Available from: http://www.R-project.org.
18. Richins P. Mount Wliitney: The Complete Trailhead-to-Summit HikingGuide. Seattle (WA): Mountaineers Books; 2001. p. 1-176.
19. Roach RC, Bartsch P, Hackett PH, et al, and the Lake Louise AMS Scoring Consensus Committee. The Lake Louise acute mountain sickness scoring system. In: Sutton JR, Houston CS, Coates G, editors. Hypoxia and Molecular Medicine. Burlington (VT): Queen City Printers; 1993. p. 272-4.
20. Roach RC, Greene ER, Schoene RB, Hackett PH. Arterial oxygen saturation for prediction of acute mountain sickness. Aviat Space Environ Med. 1998;691182-5.
21. Roach RC, Houston CS, Honigman B, et al. How well do older persons tolerate moderate altitude? West J Med. 1995;162:32-6.
22. Ross RT. The random nature of cerebral mountain sickness. Lancet. 1985;1:990-l.
23. Schneider M, Bemasch D, Weymann J, Holle R, Bartsch P. Acute mountain sickness: influence of susceptibility, preexposure, and ascent rate. Med Sci Sports Exerc. 2002;34(12):1886-91.
24. Serrano-Duenas M. High altitude headache. A prospective study of its clinical characteristics. Cephalalgia. 2005;25:1110-6.
25. Silber E, Sonnenberg P, Collier DJ, Pollard AJ, Murdoch DR, Goadsby PJ. Clinical features of headache at altitude: a prospective study. Neurol. 2003;60:1167-71.
26. Tsianos G, Woolrich-Burt L, Aitchison T, et al. Factors affecting a climber's ability to ascend Mont Blanc. Eur J Appl Physiol. 2006; 96:32-6.
27. Wagner DR, Fargo JD, Parker D, Tatsugawa K, Young TA. Variables contributing to acute mountain sickness on the summit of Mt. Whitney. Wilderness Environ Med. 2006;17:221-8.
28. Whitney Portal Store [Internet]. Lone Pine (CA); [cited 2007 Sept 17]. Available from: http://www.whitneyportalstore.com.
29. Ziaee V, Yunesian M, Ahmadinejad Z, et al. Acute mountain sickness in Iranian trekkers around Mount Damavand (5671 m) in Iran. Wilderness Environ Med. 2003;14:214-9.